Lombard Odier Asset Management Europe Ltd Acquires Shares of 136,224 Bruker Corporation $BRKR

Lombard Odier Asset Management Europe Ltd acquired a new position in Bruker Corporation (NASDAQ:BRKR) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 136,224 shares of the medical research company’s stock, valued at approximately $6,418,000.

Several other institutional investors have also added to or reduced their stakes in the business. Los Angeles Capital Management LLC purchased a new stake in Bruker during the 4th quarter valued at $26,000. Parallel Advisors LLC increased its stake in shares of Bruker by 121.0% in the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after purchasing an additional 479 shares in the last quarter. Allworth Financial LP raised its holdings in Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 257 shares during the period. Covestor Ltd raised its stake in Bruker by 304.6% during the 4th quarter. Covestor Ltd now owns 1,416 shares of the medical research company’s stock valued at $67,000 after purchasing an additional 1,066 shares during the period. Finally, Parkside Financial Bank & Trust lifted its holdings in shares of Bruker by 144.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,482 shares of the medical research company’s stock worth $70,000 after buying an additional 876 shares in the last quarter. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on BRKR shares. Barclays upped their price objective on Bruker from $45.00 to $53.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. TD Cowen raised their target price on Bruker from $43.00 to $45.00 and gave the stock a “hold” rating in a report on Thursday, May 7th. Wall Street Zen upgraded Bruker from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Weiss Ratings upgraded shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, June 3rd. Finally, UBS Group upped their price objective on shares of Bruker from $40.00 to $45.00 and gave the stock a “neutral” rating in a report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Bruker has an average rating of “Hold” and an average target price of $51.31.

Insider Buying and Selling at Bruker

In other news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total transaction of $79,800.00. Following the completion of the sale, the vice president owned 128,443 shares in the company, valued at approximately $5,124,875.70. The trade was a 1.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 27.20% of the company’s stock.

Bruker Stock Down 1.5%

BRKR stock opened at $55.80 on Wednesday. Bruker Corporation has a fifty-two week low of $28.53 and a fifty-two week high of $64.54. The company’s 50 day moving average price is $45.39 and its 200 day moving average price is $43.94. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.72 and a current ratio of 1.55. The firm has a market capitalization of $8.49 billion, a price-to-earnings ratio of -232.50, a PEG ratio of 1.81 and a beta of 1.31.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. The company had revenue of $823.40 million for the quarter, compared to the consensus estimate of $795.62 million. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The company’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.47 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities research analysts anticipate that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 7th. Shareholders of record on Monday, June 22nd will be issued a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, June 22nd. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. Bruker’s dividend payout ratio (DPR) is presently -83.33%.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.